Immunotherapy plus chemo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug sintilimab to two different chemotherapy combinations before surgery can help people with locally advanced gastric cancer that has a specific genetic feature (dMMR). You would receive treatment before surgery to shrink the tumor, then have surgery to remove it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have locally advanced stomach cancer that can be surgically removed
- Your cancer has a genetic feature called deficient mismatch repair (dMMR)
- You are in good enough health to have chemotherapy and immunotherapy before surgery (ECOG score 0-1)
- You have not had any prior chemotherapy, radiation, or immunotherapy for this cancer, or it has been more than 180 days since your last treatment
- You do not have active autoimmune diseases, severe infections, or other serious medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (ipilimumab and sintilimab) plus chemotherapy to shrink gastric cancer that cannot be surgically removed. The goal is to make the cancer small enough for surgery and improve survival.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests combining an immunotherapy drug (sintilimab) with low-dose radiation before surgery for stomach cancer that has a specific genetic marker (dMMR/MSI-H). The goal is to see if this combination can shrink the tumor and improve outcomes without needing strong chemo.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
Hear when a new Neoadjuvant Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.